NCT01962974View on ClinicalTrials.gov

A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)

PHASE3TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Arthritis, Rheumatoid
Interventions
BIOLOGICAL

Golimumab 2 mg/kg IV

Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.

Trial Locations (52)

Unknown

Birmingham

Huntsville

Peoria

Phoenix

Fort Smith

Fremont

Fullerton

Long Beach

Santa Maria

Thousand Oaks

Whittier

Bridgeport

Clearwater

Miami

Orlando

Sarasota

Tampa

Coeur d'Alene

Indianapolis

South Bend

Eagan

Edina

St Louis

Albuquerque

Orchard Park

Asheville

Charlotte

Greensboro

Hickory

Wilmington

Dayton

Duncansville

Philadelphia

Pittsburgh

Wyomissing

Charleston

Columbia

Myrtle Beach

Hixson

Jakson

Nashville

Houston

Plano

San Antonio

Arlington

Spokane

Glendale

Victoria

St. John's

Hamilton

Montreal

Rimouski

Sponsors
All Listed Sponsors
lead

Janssen Biotech, Inc.

INDUSTRY

NCT01962974 - A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®) | Biotech Hunter | Biotech Hunter